


BFW

Attorney Docket No.: 100051.00101

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Wickstrom, et al.

Serial No. 10/662,261 : Group Art Unit: 1615

Filed: September 15, 2003 : Examiner: not yet assigned

For: ADVANCED BIOMATERIALS AND METHOD OF ATTACHING
THERAPEUTIC AGENTS THERETO

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Mail Stop DD
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. Copies are provided. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.



AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to deposit account no. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP

Raymond A. Miller
Registration No. 42,891

Pepper Hamilton LLP
One Mellon Bank Center
50th Floor
500 Grant Street
Pittsburgh, PA 15219
Telephone: (412) 454-5813
Facsimile: (412) 281-0717
Date: August 4, 2004



<p>Substitute for form 1449/PATENT INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/662,261
				Filing Date	September 15, 2003
				First Named Inventor	Hickok
				Group Art Unit	1615
				Examiner Name	not yet assigned
Sheet	1	of 2		Attorney Docket Number	100051.00101

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
AA	5,268,178	B1		Calhoun	12/7/1993	

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.	T
	CA	VAUDAUX, P.; Implant-Related Factors: Biofilm and other tricks of bacteria; Symposium-Prevention and Treatment of Infection in Orthopaedic Surgery; Synos Foundation; http://www.snyos.ch/news/111-1	
	CB	MASSIA, S.P., et al.; In Vitro Assessment of Bioactive Coatings for Neural Implant Applications; J Biomed Mater Res. 2004 January 1; 68A(1):177-186	
	CC	CARSON; Efficacy of Antibiotic Impregnation of Inflatable Penile Prostheses in Decreasing Infection in Original Implants; J Urol. 2004 Apr; 171(4): 1611-4	
	CD	ARCIOLA, C.R., et al.; Staphylococcus Epidermidis-Fibronectin Binding and Its Inhibition by Heparin; Biomaterials 2003 August 24(18):3013-9	
	CE	DAROUICHE, R.O.; Antibacterial Approaches for Preventing Infections Associated with Surgical Implants; Clin Infect Dis. 2003 May 15;36(10):1284-9. Epub 2003 May 09	
	CF	POELSTRA, K.A.; Prophylactic Treatment of Gram-Positive and Gram-Negative Abdominal Implant Infections using Locally Delivered Polyclonal Antibodies; J Biomed Res. 2002 April;60(1):206-15	
	CG	VAN DE BELT, H., et al.; Infection of Orthopedic Implants and the Use of Antibiotic-Loaded Bone Cements; Acta Orthop Scand. 2001 Dec; 72(6):557-71	
	CH	NIJHOF, M.W., et al.; Prophylaxis of Implant-Related Staphylococcal Infections using Tobramycin-Containing Bone Cement; J Biomed Mater Res. 2000 Dec 15;52(4):754-61	
	CI	PENK, A., et al.; Role of Fluconazole in the Long Term Suppressive Therapy of Fungal Infections in Patients with Artificial Implants; Mycoses. 1999;42 Suppl 2:91-6	
	CJ	KUPPERMANN, B.D., et al.; Oral Ganciclovir for Patients with Cytomegalovirus Retinitis Treated with a Ganciclovir Implant; N Eng J Med. 1999 Apr 8;340(14):1109-110	
	CK	WEBER, H.P., et al.; Inhibition of Peri-Implant Bone Loss with the Nonsteroidal Anti-Inflammatory Drug Flurbiprofen in Beagle Dogs; Clin. Oral Res. 1994 Sep;5(3):148-53	
	CL	EBBINGHAUS, C., et al.; Diagnostic and Therapeutic Applications of Recombinant Antibodies: Targeting the Extra-Domain B of Fibronectin, a marker of Tumor Angiogenesis; Curr Pharm Des. 2004;10(13):1537-49	

	CM	DAROUCHE, R. O.; Treatment of Infections Associated with Surgical Implants; http://content.nejm.org/cgi/content/full/350/14/1422	
	CN	DAROUCHE, R.O.; Antimicrobial Approaches for Preventing Infections Associated with Surgical Impalnts; http://www.journals.uchicago.edu/CID/journal/issues/v36n10/30226/30226.html	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Attorney Docket No. 100051.101

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

APPLICANT: Wickstrom et al.

TITLE: ADVANCED BIOMATERIALS AND METHOD OF ATTACHING THERAPEUTIC AGENTS THERETO

SERIAL NO. 10/662,261

ATTORNEY REF: 100051.00101

DATE OF DEPOSIT: August 4, 2004

I HEREBY CERTIFY THAT THIS INFORMATION DISCLOSURE STATEMENT WITH COPIES OF REFERENCES CITED THEREIN IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE VIA FIRST CLASS MAIL UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO COMMISSIONER FOR PATENTS, MAIL STOP AMENDMENT, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Jennifer Martinez

(Typed or printed name of person mailing paper or fee)

Documents Enclosed:

1. Information Disclosure Statement with cited references;
2. Certificate of Mailing;
3. Postcard